Clinical Trial Goal
To find out:
- The highest dose of glofitamab that's safe to give with lenalidomide and obinutuzumab
- If the combination of glofitamab, lenalidomide and obinutuzumab is safe and works well to treat MCL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have MCL that has relapsed or is refractory
- Have cancer cells with mutation/marker CD20. Your doctor can tell you this
- Have not been treated with a drug that targets CD3 and CD20. Your doctor can tell you this
- Have not been treated with lenalidomide or other immunomodulatory drugs in the last 1 year
- Have not had allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Glofitamab is a bispecific monoclonal antibody that targets CD 3 and CD20 on certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Lenalidomide is a drug that blocks growth of cancer cells.
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Glofitamab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Lenalidomide – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Obinutuzumab – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat MCL that has relapsed or is refractory is new and unproven.
Contacts
Anita Kumar, MD, 646-608-3780, kumara2@mskcc.org
Gilles Salles, MD, PhD, 646-608-4153, SallesG@mskcc.org
Locations
Sponsors
collaborator: Genentech, Inc., lead: Memorial Sloan Kettering Cancer Center
